Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GC Biopharma Partners with Körber to Implement MES | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

GC Biopharma Partners with Körber to Implement MES

Will implement Körber’s PAS-X MES solution at three major manufacturing sites.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

The management teams from Körber Korea and GC Biopharma cutting a cake at the MES kick-off ceremony.

GC Biopharma, a South Korean biopharmaceutical company, has partnered with Körber to implement a large-scale Manufacturing Execution System (MES) project across multiple sites. Set to go live within a year, the project marks one of Korea’s fastest MES rollouts.

At the core of the initiative is the implementation of Körber’s PAS-X MES solution at three major manufacturing sites, including facilities producing Hunterase (a treatment for Hunter syndrome) and a range of plasma-derived therapies. The MES will serve as the digital backbone of operations, enabling real-time process visibility, batch traceability, seamless system integration, and enhanced global compliance.

“This MES project is not just about digitalization – it’s a bold step toward redefining manufacturing standards in Korea’s biopharmaceutical sector,” said Woong Shin, VP/Head of Quality Management at GC Biopharma. “Partnering with Körber reflects our shared commitment to innovation and responsibility in delivering high-quality therapies worldwide.”

The project follows a phased rollout plan, with a technical go-live scheduled in 10 months and commercial operations to begin in 14 months. GC Biopharma expects to achieve a 25% reduction in batch cycle time, a 30% improvement in data review efficiency, and full compliance with FDA 21 CFR Part 11 and EU GMP Annex 11.

“Delivering a project of this scale within such a compressed timeline demonstrates the strength of our partnership and shared ambition,” said Andrew Lee, Managing Director Korea, Körber Business Area Pharma. “We’re not just implementing a system – we’re building a foundation for digital excellence.”

This MES project is a cornerstone of GC Biopharma’s digital strategy and a catalyst for operational excellence and accelerated market responsiveness.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics